RDY
Dr. Reddy's Laboratories Limited
Stock
$12.250.00 (0.00%)Close Oct 2, 2026
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹325.5B | ₹279.2B | ₹245.9B | ₹214.4B | ₹189.7B | ₹174.6B | ₹153.9B | ₹142.0B | ₹140.8B | ₹154.7B |
| Cost of revenue | ₹135.1B | ₹115.6B | ₹106.5B | ₹100.6B | ₹86.6B | ₹80.6B | ₹70.4B | ₹65.7B | ₹62.5B | ₹62.4B |
| Gross profit | ₹190.4B | ₹163.6B | ₹139.3B | ₹113.8B | ₹103.1B | ₹94.0B | ₹83.4B | ₹76.3B | ₹78.4B | ₹92.3B |
| R&D | ₹27.4B | ₹22.9B | ₹19.4B | ₹17.5B | ₹16.5B | ₹15.4B | ₹15.6B | ₹18.3B | ₹19.6B | ₹17.8B |
| SG&A | ₹93.9B | ₹77.2B | ₹68.0B | ₹62.1B | ₹54.7B | ₹50.1B | ₹48.7B | ₹46.9B | ₹46.4B | ₹45.7B |
| Other operating expenses | — | — | — | ₹4.8B | ₹7.6B | ₹12.5B | — | — | — | — |
| Operating income | ₹71.8B | ₹67.7B | ₹57.1B | ₹29.5B | ₹24.3B | ₹16.0B | ₹20.9B | ₹11.9B | ₹13.5B | ₹29.6B |
| Non-operating income | ₹4.9B | ₹4.1B | ₹3.2B | ₹2.8B | ₹2.1B | ₹2.0B | ₹1.6B | ₹2.4B | ₹1.2B | −₹2.5B |
| Pretax income | ₹76.8B | ₹71.9B | ₹60.4B | ₹32.3B | ₹26.4B | ₹18.0B | ₹22.4B | ₹14.3B | ₹14.7B | ₹27.1B |
| Taxes | ₹20.2B | ₹16.2B | ₹15.3B | ₹8.7B | ₹9.2B | −₹1.5B | ₹3.6B | ₹4.5B | ₹2.6B | ₹7.1B |
| Net income | ₹56.5B | ₹55.7B | ₹45.1B | ₹23.6B | ₹17.2B | ₹19.5B | ₹18.8B | ₹9.8B | ₹12.0B | ₹20.0B |
| Diluted EPS | ₹67.78 | ₹66.80 | ₹54.17 | ₹141.69 | ₹103.65 | ₹117.40 | ₹113.09 | ₹59.00 | ₹72.09 | ₹116.98 |
| Diluted shares | 834.2M | 833.5M | 831.9M | 166.3M | 166.3M | 166.1M | 166.2M | 166.2M | 167.0M | 171.1M |
| Revenue growth | +16.6% | +13.5% | +14.7% | +13.0% | +8.7% | +13.5% | +8.3% | +0.9% | −9.0% | — |
| Gross margin | 58.5% | 58.6% | 56.7% | 53.1% | 54.3% | 53.8% | 54.2% | 53.7% | 55.6% | 59.6% |
| Operating margin | 22.1% | 24.3% | 23.2% | 13.7% | 12.8% | 9.2% | 13.6% | 8.4% | 9.6% | 19.1% |
| Net margin | 17.4% | 19.9% | 18.3% | 11.0% | 9.1% | 11.2% | 12.2% | 6.9% | 8.5% | 12.9% |